Synapse - Ferrata Storti Foundation

Results (357)

Nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma: Safety and efficacy outcomes from a phase 1 clinical trial

Meeting Abstract

Ansell, S.; Armand, P.; Timmerman, J.; Shipp, M.; Popa McKiver, M.; Zhu, L.; Lesokhin, A. M.
Haematologica (2016)

Fulltext@MSK | Save

Brentuximab vedotin after autologous stem cell transplant yields the strongest benefit in Hodgkin lymphoma patients with ≥2 risk factors: Results of a multivariate analysis

Meeting Abstract

Moskowitz, C.; Sweetenham, J.; Chen, A.; Ayala, E.; Masszi, T.; Holowiecki, J.; Stiff, P.; Carella, A.; Viviani, S.; Bachanova, V.; more...
Haematologica (2016)

Fulltext@MSK | Save

Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)

Meeting Abstract

Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
Haematologica (2016)

Fulltext@MSK | Save

Residual site radiation therapy: An opportunity to increase safety of combined modality therapy for early stage Hodgkin lymphoma

Meeting Abstract

Straus, D.; Cahlon, O.
Haematologica (2016)

Fulltext@MSK | Save

Sequential brentuximab vedotin and adriamycin, vinblastine, and dacarbazine for older patients with untreated Hodgkin lymphoma: Findings from a phase II Window study

Meeting Abstract

Evens, A. M.; Hamlin, P. A.; Nabhan, C.; Advani, R.; Fanale, M.; Petrich, A.; Smith, S.; Bociek, G.; Winter, J.; Gordon, L. I.
Haematologica (2016)

Fulltext@MSK | Save

Evaluation of serum TARC levels in patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma: Results from the AETHERA trial

Meeting Abstract

Bachanova, V.; Carella, A.; Masszi, T.; Holowiecki, J.; Viviani, S.; Huebner, D.; Hunder, N.; Larsen, E.; Odegard, J.; Onsum, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

CHIPS as a predictor of outcome in radiated vs unradiated HL

Meeting Abstract

Schwartz, C. L.; Wolden, S.; Constine, L. S.; Chen, L.; Friedman, D.
Haematologica (2016)

Fulltext@MSK | Save

CheckMate 205 Cohort C: Nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation

Meeting Abstract

Zinzani, P. L.; Engert, A.; Younes, A.; Santoro, A.; Ansell, S.; Timmerman, J.; Collins, G.; Armand, P.; Savage, K. J.; Trneny, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: Multicohort, phase 2 KEYNOTE-087 study

Meeting Abstract

Moskowitz, C.; Zinzani, P. L.; Fanale, M. A.; Armand, P.; Johnson, N.; Ribrag, V.; Radford, J.; von Tresckow, B.; Tomita, A.; Shipp, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Haematologica (2016)

Fulltext@MSK | Save

Ferrata Storti Foundation

People

Groups

Results (357)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Ferrata Storti Foundation – authorized name for: